Insider Selling at KalVista Pharmaceuticals (KALV) is Significant

Friday, September 15, 2017 10:15 PM ET

Insider Selling at KalVista Pharmaceuticals (KALV) is Significant

One insider — Holdings A/S Novo, 10% Owner — today, sold 176,647 shares of KalVista Pharmaceuticals having a market value of approximately $1,273,980, as indicated in a form 4 document filed with the SEC. This is the first insider buy/sell trade in the past 90 days.

The number of buy-sell trades for KalVista Pharmaceuticals is close to that of the 42 member peer company average. The Biopharmaceuticals peer group saw 28 buy/sell trades during this period for an average of 0.7 transactions per company. However, the number of shares per buy/sell trade transacted by KalVista Pharmaceuticals insiders is higher. Within the peer group there were 29,500 shares purchased and 2,299,220 shares sold with company insiders having sold 81,061 shares on average.

Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in evaluating and writing this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.